2022
Perfluoroalkyl Substances and Incident Natural Menopause in Midlife Women: The Mediating Role of Sex Hormones
Ding N, Harlow S, Randolph J, Mukherjee B, Batterman S, Gold E, Park S. Perfluoroalkyl Substances and Incident Natural Menopause in Midlife Women: The Mediating Role of Sex Hormones. American Journal Of Epidemiology 2022, 191: 1212-1223. PMID: 35292812, PMCID: PMC9393069, DOI: 10.1093/aje/kwac052.Peer-Reviewed Original Research
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataUrinary metals and metal mixtures and timing of natural menopause in midlife women: The Study of Women’s Health Across the Nation
Wang X, Ding N, Harlow S, Randolph J, Mukherjee B, Gold E, Park S. Urinary metals and metal mixtures and timing of natural menopause in midlife women: The Study of Women’s Health Across the Nation. Environment International 2021, 157: 106781. PMID: 34311223, PMCID: PMC8490279, DOI: 10.1016/j.envint.2021.106781.Peer-Reviewed Original ResearchConceptsMetal mixturesMetal concentrationsTiming of natural menopauseCox proportional hazards modelsNatural menopauseStudy of Women's HealthProportional hazards modelHazard ratioEnvironmental risk scoreLowest quartileIndividual metal concentrationsExposure to metalsUrinary metal concentrationsHazards modelMedian follow-upMonths of amenorrheaWomen's HealthAssociated with earlier natural menopauseEarly natural menopauseUrinary metalsNation Multi-Pollutant StudyBleeding episodesHormone therapyPremenopausal womenMedian agePer- and Polyfluoroalkyl Substances and Hormone Levels During the Menopausal Transition
Harlow S, Hood M, Ding N, Mukherjee B, Calafat A, Randolph J, Gold E, Park S. Per- and Polyfluoroalkyl Substances and Hormone Levels During the Menopausal Transition. The Journal Of Clinical Endocrinology & Metabolism 2021, 106: e4427-e4437. PMID: 34181018, PMCID: PMC8677593, DOI: 10.1210/clinem/dgab476.Peer-Reviewed Original ResearchConceptsMidlife womenSex hormone-binding globulinFollicle-stimulating hormoneInverse associationStudy of Women's HealthPositive associationMenopausal transitionBody mass indexReproductive ageWomen's HealthSignificant linear trendNo significant associationNulliparous womenLinear mixed modelsSmoking statusYears of ageMass indexHormone-binding globulinMenopausal statusLongitudinal serum concentrationsSignificant associationSerum PFAS concentrationsMidlifeWomenPolyfluoroalkyl substances
2020
Associations of Perfluoroalkyl Substances with Incident Natural Menopause: The Study of Women’s Health Across the Nation
Ding N, Harlow S, Randolph J, Calafat A, Mukherjee B, Batterman S, Gold E, Park S. Associations of Perfluoroalkyl Substances with Incident Natural Menopause: The Study of Women’s Health Across the Nation. The Journal Of Clinical Endocrinology & Metabolism 2020, 105: dgaa303. PMID: 32491182, PMCID: PMC7418447, DOI: 10.1210/clinem/dgaa303.Peer-Reviewed Original ResearchConceptsStudy of Women's HealthNatural menopauseHazard ratioSerum concentrationsWomen's HealthCohort of midlife womenConfidence intervalsCalculate hazard ratiosAdverse health outcomesPFAS serum concentrationsMonths of amenorrheaAssociation of perfluoroalkyl substancesEarly natural menopauseBaseline serum concentrationsCox proportional hazards modelsAssociated with earlier natural menopauseIsotope dilution tandem mass spectrometryHealth outcomesProportional hazards modelReverse causationBleeding episodesMidlife womenLowest tertileMedian timeHormone use
2016
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
Lee A, Bomkamp A, Bandera E, Jensen A, Ramus S, Goodman M, Rossing M, Modugno F, Moysich K, Chang‐Claude J, Rudolph A, Gentry‐Maharaj A, Terry K, Gayther S, Cramer D, Doherty J, Schildkraut J, Kjaer S, Ness R, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah P, Chenevix‐Trench G, Olson S, Hogdall E, Wu A, Pike M, Stram D, Pearce C, Consortium F. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal Of Cancer 2016, 139: 2646-2654. PMID: 27420401, PMCID: PMC5500237, DOI: 10.1002/ijc.30274.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAllelesAlternative SplicingCase-Control StudiesDisease SusceptibilityEstrogen Replacement TherapyFemaleGene-Environment InteractionGenome-Wide Association StudyGenotypeHumansMenopauseMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotidePopulation SurveillanceRiskTelomeraseConceptsOvarian Cancer Association ConsortiumEstrogen-alone therapyOvarian cancer riskEndometrioid ovarian cancerOvarian cancerET usersET useT alleleAssociated with ovarian cancer riskCancer riskLong-term ET usersOvarian cancer susceptibility lociRisk of ovarian cancerSusceptibility variantsMenopausal estrogen therapyCancer susceptibility lociSerous ovarian cancerSplice variantsNon-usersCase-control studyConditional logistic regressionGenome-wide association studiesIncreased risk of diseaseEndometrioid histotypeEstrogen therapy